Katherine Breedis

Stifel Nicolaus has started coverage on Gilead Sciences, Inc. (NASDAQ: GILD) with a Buy rating and $100 target price on improving HCV stability and pipeline profile over the next 12 months, especially NASH (Nonalcoholic Steatohepatitis), a disease area of high unmet medical need. NASH Pipeline The...